Ask AI
ProCE Banner Activity

Expert Strategies in Heart Failure Care: Improving the Utilization of GDMT and SLGT2 Inhibitors to Enhance Patient Outcomes

Clinical Thought

Gain expert-informed strategies for improving the delivery of guideline-directed medical therapy for patients with heart failure across the ejection fraction spectrum, including key considerations for using SGLT2 inhibitors, and what lies ahead in the future of heart failure care.

Released: December 15, 2025

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company.

Boehringer Ingelheim Pharmaceuticals, Inc.

Eli Lilly and Company

Target Audience

This activity is intended for cardiology physicians, nurse practitioners, and physician associates who care for patients with heart failure. 

Program Learning Goal

The goal of this activity is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Heart Failure.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify key clinical gaps in heart failure management and emphasize the role of guideline-directed medical therapy in improving outcomes 

  • Assess the efficacy, safety, and cardiovascular benefits of early and sustained SGLT2 inhibitor use in heart failure treatment

  • Develop and implement practical strategies to integrate SGLT2 inhibitors into personalized care plans for patients with heart failure across the spectrum on left ventricular ejection fraction

Faculty Disclosure

Primary Author

Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC, has no relevant financial relationships to disclose.